Pacific’s Cxbladder tests receive approval for use in public healthcare sector


  • Pacific Edge on its way to commercialise Cxbladder tests through DHB.
  • The DHB, being in the public health domain, has a vast reach.
  • Pacific Edge envisions a time when Cxbladder is the world leader for urothelial cancer diagnosis.

In a recent announcement, Pacific Edge Limited (NZX: PEB) revealed that  its product, Cxbladder  products, had received approval from NZ Public Healthcare Providers for use in the public healthcare sector. The District Health Board of Northland is all set to adopt the full range of Cxbladder tests, increasing the range of services for the Organisation by manifold.

Image Source: Copyright © 2021 Kalkine Media

The Company has reached an agreement with the prestigious Mahiti Hauora and the Northland DHB, the District Health Board for starting the use of the Cxbladder range of products. This is a step in making  Cxbladder range of products ready for nationwide usage.

This will extend the reach of Cxbladder throughout NZ’s public healthcare providers.

Northland DHB covers a population size of 190,000 of New Zealand in the northernmost parts. Of this population, one third is Maori population and the rest are in the ageing population group.

Under the new programme, patients with blood in their urine will be referred for the Cxbladder’s test.

Targeting even the remotest parts of the country, the Company aims at providing these tests to patients via their DHB to save their time and money and help them get the treatment they need at the earliest.

Don’t miss : Telix (ASX:TLX) starts Phase 3 clinical trial of prostate cancer therapy

Strategy for further growth

In Its annual report released in the end of June 2021, the Company had stated its intention of spreading further the use of their Cxbladder range of products in the country. They have in action strategies for the expansion of their business globally as well as within New Zealand.

The Company considers it as a vision to be able to make Cxbladder the most widely used and trusted brands when it comes to detection and diagnostic tests for urothelial cancer.

Also read: Why Are These 5 NZX Stocks Drawing Investors’ Attention Today- FPH, SEK, PEB, FWL, AFT

The Company plans to leverage their USP as being a finished product in the New Zealand market. The cost and time that would be incurred in creating a similar or better product is something that the Company is banking upon.

Also read: Which 5 NZX stocks witnessed the highest trading volumes on Tuesday?

While New Zealand is already the global leader for the testing and adaptation of Cxbladder as a trusted test, the Company plans to make their name unanimous with testing for this kind of cancer, with these products eventually becoming the only ones trusted for testing.

Highlighting the brand’s benefits through performance, the Company believes it is in a good position to pursue the remaining health care providers to give a serious thought to adapt Cxbladder as their choice of tests. Health New Zealand, the new country wide health service, is being aimed by Pacific Edge to strategise the uniform increase of Cxbladder tests in the country.

Read: US indices slip after last week's record closes

Also read: Imugene presents encouraging data on HER-Vaxx at ESMO World Congress on GI Cancer 2021

Testing international waters

The aim of the organisation is to gradually grow from strength to strength and become a globally recognised brand. Recently, Kaiser Permanente, an integrated care consortium, based out of Oakland, California, has approved the use of a second Cxbladder product for regular usage in their facility. This shows that these products are user friendly, and they could be a major help in critical patient diagnosis and care for cancer patients.



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK